- Home
- TAK vs RMD Comparison
TAK vs RMD Comparison
Compare TAK & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- RMD
- Stock Information
- Founded
- TAK 1781
- RMD 1989
- Country
- TAK Japan
- RMD United States
- Employees
- TAK N/A
- RMD N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- RMD Medical/Dental Instruments
- Sector
- TAK Health Care
- RMD Health Care
- Exchange
- TAK Nasdaq
- RMD Nasdaq
- Market Cap
- TAK 47.3B
- RMD 40.7B
- IPO Year
- TAK N/A
- RMD 1995
- Fundamental
- Price
- TAK $15.08
- RMD $271.19
- Analyst Decision
- TAK
- RMD Buy
- Analyst Count
- TAK 0
- RMD 13
- Target Price
- TAK N/A
- RMD $276.82
- AVG Volume (30 Days)
- TAK 3.1M
- RMD 951.7K
- Earning Date
- TAK 10-30-2025
- RMD 10-23-2025
- Dividend Yield
- TAK 3.60%
- RMD 0.88%
- EPS Growth
- TAK N/A
- RMD 37.43
- EPS
- TAK 0.59
- RMD 9.51
- Revenue
- TAK $31,053,301,865.00
- RMD $5,146,327,000.00
- Revenue This Year
- TAK $0.40
- RMD $9.83
- Revenue Next Year
- TAK $0.83
- RMD $7.29
- P/E Ratio
- TAK $25.50
- RMD $28.56
- Revenue Growth
- TAK 1.52
- RMD 9.84
- 52 Week Low
- TAK $12.80
- RMD $199.92
- 52 Week High
- TAK $15.69
- RMD $293.81
- Technical
- Relative Strength Index (RSI)
- TAK 50.98
- RMD 43.88
- Support Level
- TAK $14.87
- RMD $269.00
- Resistance Level
- TAK $15.38
- RMD $281.32
- Average True Range (ATR)
- TAK 0.18
- RMD 5.34
- MACD
- TAK -0.02
- RMD -1.41
- Stochastic Oscillator
- TAK 32.97
- RMD 26.61
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About RMD ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.